RecruitingNot applicableNCT07356531
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
Studying Rare tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- JIANGSU SHENMING Medical Technology CO., Ltd
- Intervention
- Transcatheter Arterial Chemoembolization(device)
- Enrollment
- 216 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2024 – 2026
Study locations (15)
- Anhui Provincial Hospital, Hefei, Anhui, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- Affiliated Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China
- The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
- The Fourth Hospital of Hebei Medical University (Hebei Provincial Cancer Hospital), Shijiazhuang, Hebei, China
- Anyang Tumor Hospital, Anyang, Henan, China
- The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Yichang Central People's Hospital, Yichang, Hubei, China
- First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- Jilin Guowen Hospital, Gongzhuling, Jilin, China
- Shanxi Bethune Hospital, Taiyuan, Shanxi, China
- Lishui Central Hospital, Lishui, Zhejiang, China
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07356531 on ClinicalTrials.govOther trials for Rare tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT04145141National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNANCT02984566Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)University of Sydney
See all trials for Rare tumor of liver and intrahepatic biliary tract →